TY - JOUR
T1 - Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis
AU - WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group
AU - Edler, Peta
AU - Rajasekhar, Megha
AU - Price, David J.
AU - Adam, Ishag
AU - Awab, Ghulam Rahim
AU - Barber, Bridget E.
AU - Brasil, Larissa W.
AU - Chamma-Siqueira, Nathália N.
AU - Chu, Cindy S.
AU - Cui, Liwang
AU - Daher, André
AU - Gomes, Margarete do Socorro M.
AU - Gonzalez-Ceron, Lilia
AU - Grigg, Matthew J.
AU - Karunajeewa, Harin
AU - Lacerda, Marcus V.G.
AU - Ladeia-Andrade, Simone
AU - Leslie, Toby
AU - Ley, Benedikt
AU - Lidia, Kartini
AU - Llanos-Cuentas, Alejandro
AU - Longley, Rhea J.
AU - Manning, Laurens
AU - Mekonnen, Daniel Abebe
AU - Monteiro, Wuelton Marcelo
AU - Moore, Brioni R.
AU - Nosten, Francois
AU - Pasaribu, Ayodhia Pitaloka
AU - Pereira, Dhelio B.
AU - Poespoprodjo, Jeanne Rini
AU - Pukrittayakamee, Sasithon
AU - Rijal, Komal Raj
AU - Saravu, Kavitha
AU - Siqueira, André M.
AU - Sutanto, Inge
AU - Taylor, Walter R.J.
AU - Thanh, Pham Vinh
AU - Thriemer, Kamala
AU - Vieira, José Luiz F.
AU - White, Nicholas J.
AU - Yeshiwondim, Asnakew K.
AU - Zuluaga-Idarraga, Lina M.
AU - Guerin, Philippe J.
AU - Simpson, Julie A.
AU - Price, Ric N.
AU - Commons, Robert J.
AU - Woyessa, Adugna
AU - Woon, Sze Ann
AU - Woodrow, Charles J.
AU - William, Timothy
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Background: The antirelapse efficacy of primaquine is related to the total dose administered, whereas the risks of haemolysis and gastrointestinal intolerance are associated with the daily dose administered. National Malaria Control Programmes require local information on efficacy, tolerability and safety to optimize antimalarial treatment policies for Plasmodium vivax malaria control and elimination efforts. Methods: A living systematic review identified efficacy studies of uncomplicated P. vivax malaria including patients treated with daily primaquine regimens, published since January 1, 2000. Available data were pooled and an R Shiny app was developed to integrate statistical analyses performed using R and Stata that assessed the impact of primaquine mg/kg dose on efficacy, hematological safety and gastrointestinal tolerability. Results: As of January 16, 2025, a total of 9,270 individual patient data records from 41 studies have been collated into the standardized repository. Open-access automated reports were generated for user-selected countries or regions to investigate location specific effects of primaquine dose on efficacy, safety and tolerability. The reports include visual and tabular displays of the outcomes. Conclusions: These automated reports leverage a large database to provide accessible data for national and regional policy makers and researchers to assess the clinical consequences of different primaquine regimens in different endemic settings. The reports will inform local and regional policy decisions and research priorities in vivax-endemic areas.
AB - Background: The antirelapse efficacy of primaquine is related to the total dose administered, whereas the risks of haemolysis and gastrointestinal intolerance are associated with the daily dose administered. National Malaria Control Programmes require local information on efficacy, tolerability and safety to optimize antimalarial treatment policies for Plasmodium vivax malaria control and elimination efforts. Methods: A living systematic review identified efficacy studies of uncomplicated P. vivax malaria including patients treated with daily primaquine regimens, published since January 1, 2000. Available data were pooled and an R Shiny app was developed to integrate statistical analyses performed using R and Stata that assessed the impact of primaquine mg/kg dose on efficacy, hematological safety and gastrointestinal tolerability. Results: As of January 16, 2025, a total of 9,270 individual patient data records from 41 studies have been collated into the standardized repository. Open-access automated reports were generated for user-selected countries or regions to investigate location specific effects of primaquine dose on efficacy, safety and tolerability. The reports include visual and tabular displays of the outcomes. Conclusions: These automated reports leverage a large database to provide accessible data for national and regional policy makers and researchers to assess the clinical consequences of different primaquine regimens in different endemic settings. The reports will inform local and regional policy decisions and research priorities in vivax-endemic areas.
KW - Automated report
KW - Dose
KW - Efficacy
KW - Haemolysis
KW - Malaria
KW - Plasmodium vivax
KW - Primaquine
KW - Recurrence
KW - Relapse
KW - Tolerability
UR - https://www.scopus.com/pages/publications/105021980758
U2 - 10.1186/s12936-025-05642-w
DO - 10.1186/s12936-025-05642-w
M3 - Artículo
C2 - 41239453
AN - SCOPUS:105021980758
SN - 1475-2875
VL - 24
JO - Malaria Journal
JF - Malaria Journal
IS - 1
M1 - 400
ER -
SDG 3 Good Health and Well-being